apoQlar is revolutionizing medical imaging and surgery with its advanced Mixed Reality (MR) and VR platforms, with clinical applications being CE marked and FDA approved, demonstrating a commitment to compliance and safety on a global scale. Operating across Europe, Asia, the Americas, and Oceania, the company boasts a diverse international team dedicated to enhancing medical outcomesthrough cutting-edge technology.
apoQlar has revolutionized healthcare delivery through its groundbreaking development in the field of holographic medicine. By harnessing advancedholographic imaging technologies, apoQlar enables medical professionals to visualize complex medical data and patient anatomy in three dimensions. The integration of artificial intelligence (AI) into their Holomedicine® solutions further tailors applications across all medical fields, significantly enhancing clinical decision-making and positively impacting patient outcomes. Among many different applications, this innovative approach enhances medical collaboration, facilitates surgical planning, and improves educational opportunities for healthcare providers, thereby settingnew standards in patient care and medical the infusion of capital will accelerate apoQlar’s product development, expand its distribution
training networks, and enhance regulatory and research capabilities to meet growing global demand.
Sirko Pelzl, CEO of apoQlar, remarked, “This Series A funding represents a pivotal point in apoQlar’s journey. With the support of our esteemed investors and our dedicated team across four continents, we are poised to push the boundaries of what’s possible in medical technology. Our commitment to medicalevidence and innovation remains at the forefront as we expand our impact worldwide.”
Markus Feuerecker, Founding Partner of lead investor YZR Capital, stated, “YZR is committed to fostering innovative solutions that have the potential to redefine industries. apoQlar’s impressive track record and the tangible benefits its products bring to the healthcare sector made it a compelling addition to our portfolio. We are excited to support apoQlar as they scale up operations and set new benchmarks in medical technology.”
Dörte Bunge, Principal beim Innovationsstarter Fonds at IFB Innovationsstarter GmbH expressed, “IFB Innovationsstarter is proud to contribute to apoQlar’s growth as they continue to demonstrate remarkable innovation and dedication in the health-tech landscape. Their technology is not just
revolutionary but crucial for the future of medical imaging and surgical precision. We look forward to seeing their continued success on the global stage out of Hamburg.”
apoQlar is also exploring strategic investments in the market to further entrench its leadership in the health-tech industry.
For media inquiries, please contact:
Alexander Kopf, COO; alexander.kopf@apoqlar.com
About apoQlar
apoQlar specializes in augmented reality technologies, artificial intelligence and computer vision that transform medical imaging and surgeries. With a robust international presence and a focus on compliance and efficacy validated by CE marking and FDA approval, apoQlar is committed to advancing healthcare outcomes through innovation. For more information, visit [www.apoqlar.com] https://www.apoqlar.com
About YZR Capital
YZR Capital invests in high-potential healthtech startups that are poised to disrupt the industry. With a focus on sustainable and scalable innovation, YZR supports companies that are ready to lead their fields. Learnmore at [www.yzr.vc](http://www.yzr.vc).
About Innovationsstarter Fonds Hamburg GmbH
Innovationsstarter Fonds Hamburg GmbH invests venture capital in young innovative companies in order to strengthen the Hamburg start-up scene with equity, support them in their further growth and contribute to the development of promising companies. Open investments up to a maximum of EUR 7,0 million per company through the InnoVentureProgram are planned. 70% of the funds come from the federal government or KfW and 30% from the Free and Hanseatic City of Hamburg (FHH). The fund is managed by IFB Innovationsstarter GmbH, a wholly owned subsidiary of Hamburgische Investitions- und Förderbank. More information can be found at www.innovationsstarter.com.
Contact:
IFB Innovationsstarter GmbH Dörte Bunge
Besenbinderhof 31, 20097 Hamburg
T.: +49 40 657980595
bunge@innovationsstarter.com https://innovationsstarter.com/